2 replies to this topic

[Coffeee]

Does any one know what the effects would be?
 

its an amino acid.....theres no studies on it.....

[Supierce]

The standard seems to be around 20g/day, so I doubt it would be too harmful. And there are quite a few studies - check this thread:

http://www.longecity...e-be-taking-it/

Edited by Supierce, 03 July 2015 - 02:33 AM.

[Darryl]

Glycine doesn't have a chiral center, so there's no L-enantiomer.

 

And sure there are studies at those doses. Psychiatrists will try just about anything.

 

Heresco-Levy U et al. 1999. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of general psychiatry,56(1), 29-36.

Twenty-two treatment-resistant schizophrenic patients participated in a double-blind, placebo-controlled, 6-week, crossover treatment trial with 0.8 g/kg per day of glycine

 

Glycine treatment was well tolerated and induced increased glycine (P=.001) and serine (P=.001) serum levels. Glycine administration resulted in (l) a significant (P<.001) 30%±16% reduction in negative symptoms, as measured by the PANSS; and (2) a significant (P<.001) 30%±18% improvement in the Brief Psychiatric Rating Scale total scores. Low pretreatment glycine serum levels significantly predicted (r=0.80) clinical response.

 

Glycine treatment led to a highly significant 3.5-fold increase in serum glycine levels across subjects 

 

(One) patient was withdrawn at week 6 of glycine treatment because of upper gastrointestinal tract discomfort with nausea and vomiting that ceased following discontinuation of glycine treatment. Glycine and serine serum levels at withdrawal were 676 nmol/mL (reference range, 100-450 nmol/mL) and 491 nmol/mL (reference range, 75-200 nmol/mL), respectively. For all subjects, clinical laboratory parameters were unaffected by treatment.

 

0.8 g/kg per day of glycine is 48 g for a 60 kg (132 lb) person, 64 g for a 80 kg (176 lb) one.

 

 

Greenberg WM et al. 2009. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. Journal of psychiatric research, 43(6), 664-670.

We enrolled 24 adult outpatients with OCD on stabilized treatment regimens in a double-blind trial of adjunctive glycine, an NMDA glutamate receptor agonist. Participants were randomly assigned 1:1 to either placebo or glycine titrated to 60 g/day, with follow-up visits scheduled at 4, 8 and 12 weeks

 

Those receiving glycine (n = 5) experienced a mean decrease of 6.04 points in Yale-Brown Obsessive Compulsive Scale score, compared with a 1.00 point decrease for those receiving placebo (n = 9). Using a hierarchical linear model, compared with placebo, individuals who received glycine had an average 0.82 decrease in Y-BOCS score for each week they remained in the study, not quite reaching statistical significance (p = 0.053). Two of those receiving glycine were responders, versus none receiving placebo (p = 0.11, ns, Fisher exact). Despite the dropouts, two participants were known to have subsequently continued taking glycine through their regular treating psychiatrist for over a year.

 

The glycine condition approached efficacy for treatment of OCD in this study, with the high dropout rate related to problems with palatability

 

Of the 16 who discontinued at any time, 8 dropped out due to complaints of nausea or disagreeable taste, 1 for constipation, 2 for perceived lack of efficacy, 2 because of desire for a medication change, 1 because of difficulty remembering to carry study medication between two residences, 1 was completely lost to follow-up, and 1 was discontinued because of consistent non-adherence

 

The principal limitations of our study are the small sample size and high dropout rate, the latter probably reflecting the relatively large doses (60 g/day) of glycine required for effective NMDA agonist action in the brain; participants complained of the fluid volume

and very sweet taste. 

 

However, despite the discontinuations related to complaints about the taste, at least two participants continued taking glycine for more than one year after study completion, arranging to obtain it commercially with oversight of their treating psychiatrists. Although as a group participants were not able to accurately guess whether they had been receiving the active condition, some who were correct were emphatic; for example, one participant insisted she must have been getting glycine (she was correct), explaining that it was ‘‘either that or magic.” Such individual experiences were encouraging, and are consistent with the other aforementioned reports of beneficial, albeit not randomized and blinded, glutamatergic interventions in treating symptoms of some individuals with OCD.

 

Edited by Darryl, 03 July 2015 - 03:05 AM.